Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T

CD19-targeted chimeric antigen receptor T lymphocytes (CAR-T) has demonstrated a high proportion of complete remission in the treatment of relapsed refractory acute B cell lymphoblastic leukemia (r/r B-ALL). It is of great clinical significance to explore which factors will impact long-term disease-...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiqi, Li, Jiasi, Zhang, Lvzhe, Chen, Huailong, Xu, Liping, He, Lin, Liu, Qianzhen, Zhang, Zhongtao, Yuan, Junjie, Shen, Zucong, Chen, Yingzi, Zhang, Meiling, Wang, Yunyan, Li, Linling, Wang, Lihua, Fang, Yingnian, Chen, Wei, Zhu, Yu, Li, Le, Luo, Youcheng, Wang, Dingsong, Zhang, Yancheng, Dong, Ping, Yin, Lihua, Zhang, Xiaoping, Li, Xiaozhuang, Hu, Zhongzheng, Zheng, Zhi, Yang, Cheng, Qian, Sanbin, Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196916/
https://www.ncbi.nlm.nih.gov/pubmed/37215385
http://dx.doi.org/10.1016/j.omto.2023.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196916/
https://www.ncbi.nlm.nih.gov/pubmed/37215385
http://dx.doi.org/10.1016/j.omto.2023.04.003

Ejemplares similares